Publications by authors named "Jim Growcott"

Claim this Profile
Q
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival.
Campbell Tait, David Moore, Clare Hodgson, Michael Brown, Thomas Morris, Jim Growcott

BJU Int· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients.
David J Moore, Alastair Greystoke, Fouziah Butt, Jens Wurthner, Jim Growcott

Clin Drug Investig· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Kate F Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Jim Growcott

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.
Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P Heaton, Jim Growcott

Mol Cancer Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
D Ross Camidge, Mike Pemberton, Jim Growcott, Dereck Amakye, David Wilson

Cancer Chemother Pharmacol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers.
D Ross Camidge, Dominic Smethurst, Jim Growcott, Nigel C Barrass, John R Foster

Cancer Chemother Pharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans.
Sanchoy Sarkar, Anthony R Hobson, Andrew Hughes, Jim Growcott, Clifford J Woolf

Gastroenterology· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the reproducibility of intradermal administration of capsaicin as a model for inducing human pain.
Andrew Hughes, Angela Macleod, Jim Growcott, I Thomas

Pain· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis